NFKB1 and neoplasm: The results in in-vivo models confirmed the hypothesis that YGS might inhibit tumor immune escape by sensitizing CRC stem cells via the NF-κB pathway through targeting TLR4, and YGS could inhibit the EMT process of CRC at the tissue level.